Testosterone Enanthate Regulatory Status: US, EU, Canada, and UK

What Is Testosterone Enanthate and How Does It Work?

Testosterone enanthate is a synthetic ester of endogenous testosterone attached to an enanthate (heptanoate) side chain at the 17-beta hydroxyl position. After intramuscular injection, esterases in blood and tissue cleave the ester bond, releasing free testosterone into circulation over approximately 4 to 5 days [1]. This slow release is what separates it from testosterone suspension or propionate, both of which have shorter activity windows.

Mechanism of Action at the Cellular Level

Free testosterone enters target cells and binds the androgen receptor (AR) in the cytoplasm. The testosterone-AR complex translocates to the nucleus, where it acts as a ligand-activated transcription factor, modulating expression of androgen-responsive genes [2]. This drives the canonical androgenic effects: nitrogen retention, erythropoiesis (via renal erythropoietin stimulation), bone mineral density maintenance, and spermatogenesis regulation via hypothalamic-pituitary feedback [2].

Testosterone also undergoes peripheral conversion. Aromatase (CYP19A1) converts a fraction to 17-beta-estradiol, and 5-alpha-reductase converts another fraction to dihydrotestosterone (DHT). Both metabolites contribute to clinical effects and adverse-event profiles [3].

Pharmacokinetics: What the Numbers Show

After a single 200 mg IM injection in eugonadal men, serum testosterone peaks at roughly 1,100 ng/dL at 24 to 48 hours, then falls to near-baseline by day 14 [1]. The elimination half-life of the ester is approximately 4.5 days. In clinical practice, weekly dosing of 100 to 200 mg produces more stable trough levels than the traditional every-two-week schedule listed on the FDA label, a point addressed in AACE guidelines [4].

The T-Trials (N=790, mean age 72 years) published in NEJM in 2016 found that one year of testosterone treatment (targeting a serum level of 500 to 1,000 ng/dL) improved sexual activity scores by 2.9 points on the PDAS scale versus 0.9 for placebo (P<0.001), increased 6-minute walk distance by a mean of 9.7 meters more than placebo (P=0.03), and improved fatigue scores on the PROMIS scale [5]. The trial used a testosterone gel formulation, but the pharmacodynamic targets and serum level goals apply directly to enanthate dosing in clinical practice.

United States: FDA Approval and DEA Schedule III Status

Testosterone enanthate holds FDA approval for the treatment of male hypogonadism, specifically primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired), under NDA/ANDA pathways for multiple manufacturers [6]. The branded reference product Delatestryl (Endo Pharmaceuticals) carries the original approval; numerous generic formulations are also FDA-approved.

Controlled Substance Classification

The Drug Enforcement Administration classifies testosterone enanthate as a Schedule III controlled substance under the Anabolic Steroid Control Act of 1990, later amended by the Anabolic Steroid Control Act of 2004 [7]. Schedule III status means:

• Prescriptions may not be refilled more than five times within six months of the original issue date.
• Written, electronic, or oral prescriptions are all permitted (unlike Schedule II, which bars oral prescriptions for non-emergency use).
• Practitioners must be DEA-registered to prescribe.
• Dispensing without a valid prescription carries felony-level penalties.

Possession for non-medical purposes is a federal offense. Athletes and bodybuilders who obtain it without a prescription face both federal drug charges and sports-governing-body sanctions [7].

FDA-Approved Indications vs. Off-Label Use

The FDA label covers male hypogonadism only [6]. Prescribing testosterone enanthate for female androgen deficiency, gender-affirming hormone therapy, or age-related androgen decline without a formal hypogonadism diagnosis is off-label. Telehealth platforms, including HealthRX, require documented lab confirmation of low testosterone (typically two morning total testosterone measurements below 300 ng/dL, consistent with Endocrine Society guidelines) before initiating therapy [4].

The FDA issued a 2015 drug safety communication requiring all testosterone products to carry a label warning about the unestablished benefits and potential cardiovascular risks of prescribing for age-related testosterone decline ("low T") without classic hypogonadism [8].

European Union: National Authorizations Without Centralized EMA Approval

The European Medicines Agency (EMA) has not granted a centralized marketing authorization for testosterone enanthate. Instead, individual member states issue national marketing authorizations under their own competent authorities [9]. This creates a patchwork of brand names, approved indications, and labeling language across the EU.

Country-Level Examples

Germany: Testosterone enanthate is available as Testoviron Depot (Bayer) and authorized by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for male hypogonadism and delayed puberty. It is prescription-only (verschreibungspflichtig) and listed as a doping agent under the German Anti-Doping Act (AntiDopG), which criminalizes non-medical possession above personal-use quantities [9].

France: Androtardyl (testosterone enanthate 250 mg/mL) holds a marketing authorization from the Agence nationale de sécurité du médicament (ANSM). French prescribers follow HAS (Haute Autorité de Santé) guidelines, which restrict initiation to endocrinologists or urologists documenting two fasting morning testosterone levels below 3.0 nmol/L with consistent symptoms.

Spain: Plenaxis and generic equivalents are authorized by the AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) under similar male hypogonadism indications.

EU Anabolic Steroid Status

Across the EU, testosterone and its esters are uniformly classified as anabolic steroids. The Council of Europe Anti-Doping Convention and the World Anti-Doping Agency (WADA) Prohibited List classify exogenous testosterone as prohibited in-competition and out-of-competition for athletes [10]. Importation across EU member state borders without a valid prescription constitutes a customs and medicines-law violation in virtually all member states.

Canada: Schedule IV Controlled Drug Under the CDSA

Health Canada classifies testosterone enanthate as a Schedule IV controlled drug under the Controlled Drugs and Substances Act (CDSA) [11]. Schedule IV in Canada is less restrictive than Schedule III in the US but still mandates:

• A written or electronic prescription from a licensed Canadian practitioner.
• No telephone (verbal) prescriptions for Schedule IV drugs without subsequent written confirmation.
• Record-keeping by pharmacies for at least two years.
• Prohibition on international mail-order importation without a Health Canada import permit.

Approved Canadian Indications

Health Canada has authorized testosterone enanthate (available as Delatestryl, 200 mg/mL) for male hypogonadism and metastatic breast cancer in women, the breast cancer indication reflecting older oncology practice that predates modern aromatase inhibitor use [11]. The Society for Endocrinology and the Canadian Urological Association align their diagnostic thresholds with Endocrine Society guidance: two morning total testosterone measurements below 300 ng/dL (10.4 nmol/L) with consistent symptoms before treatment initiation [4].

Gender-Affirming Care in Canada

Canadian guidelines from CAMH and the Canadian Professional Association for Transgender Health (CPATH) endorse testosterone therapy, most commonly testosterone enanthate or cypionate, for transmasculine patients. Prescribing in this context is legal and covered under some provincial drug benefit formularies, though it remains an off-label use of the approved hypogonadism indication [12].

United Kingdom: POM and Class C Controlled Drug

In the United Kingdom, testosterone enanthate carries dual legal status: it is a Prescription Only Medicine (POM) under the Human Medicines Regulations 2012 AND a Class C controlled drug under the Misuse of Drugs Act 1971, as amended in 2012 to include anabolic steroids [13].

What Class C Means in Practice

Class C is the least severe controlled drug category in the UK (below Class A and B), but possession without a prescription is still a criminal offense carrying up to two years imprisonment. Supply without authorization carries up to 14 years [13]. The MHRA enforces medicines law while the Home Office governs the Misuse of Drugs Regulations 2001, which list testosterone enanthate in Schedule 4, Part II, permitting personal importation of up to three months' supply for personal medical use.

MHRA-Authorized Products

The MHRA has authorized Testobolin, Nebido (a different ester, testosterone undecanoate), and various generic testosterone enanthate vials. Prescribers in England operate under NHS England clinical commissioning guidance, which generally reserves testosterone therapy initiation for secondary care endocrinologists or urologists, with shared-care agreements for GP continuation prescribing [14].

NICE and BSH Guidance

The British Society for Sexual Medicine (BSSM) 2017 guidelines state: "Testosterone therapy should only be initiated when two early morning serum total testosterone measurements confirm a value below 12 nmol/L (346 ng/dL), in the presence of consistent clinical symptoms" [14]. NICE has not issued a standalone testosterone guideline but references BSSM criteria in its menopause and hypogonadism-related technology appraisals.

A 2020 BMJ review (N=approximately 3,000 UK hypogonadal men followed for median 4.3 years) found no statistically significant increase in major adverse cardiovascular events (MACE) with testosterone therapy when prescribed according to guideline thresholds, with a hazard ratio of 1.07 (95% CI 0.89 to 1.29, P=0.47) [15].

How Testosterone Enanthate Compares to Other Formulations by Jurisdiction

Not every testosterone formulation is available in every jurisdiction. The table below synthesizes approval status across the four regions covered.

| Formulation | US (FDA) | EU (national) | Canada (HC) | UK (MHRA) | |---|---|---|---|---| | Testosterone enanthate IM | Approved | Approved (most states) | Approved | Approved | | Testosterone cypionate IM | Approved | Not widely authorized | Approved | Limited | | Testosterone undecanoate oral | Approved (Jatenzo) | Approved (Andriol) | Approved | Approved (Restandol) | | Testosterone undecanoate IM | Approved (Aveed) | Approved (Nebido) | Approved | Approved (Nebido) | | Testosterone gel | Approved | Approved | Approved | Approved | | Testosterone pellets | Approved | Limited | Not approved | Not approved |

Enanthate's relatively low cost, long clinical track record dating to its first synthesis in 1952, and wide generic availability make it the default IM formulation in North America and much of Europe [1].

Diagnostic Thresholds That Determine Legal Prescribing

Regulatory approval does not equal unrestricted prescribing. Each jurisdiction's medical licensing body sets diagnostic criteria that define lawful versus unlawful prescribing even when a practitioner holds a valid DEA or GMC registration.

Endocrine Society 2018 Guidelines

The Endocrine Society's 2018 Clinical Practice Guideline on Male Hypogonadism states: "We recommend confirming the diagnosis by repeating the measurement of serum total testosterone... We suggest against making the diagnosis of androgen deficiency in men with acute or subacute illness" [4]. The guideline further recommends against population-based testosterone screening in the absence of symptoms.

FDA 2015 Safety Communication

The FDA's 2015 safety communication explicitly states that "the benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man's symptoms seem related to low testosterone" [8]. This language, now embedded in every US testosterone product label, distinguishes age-related decline from pathological hypogonadism and has direct medicolegal implications for prescribers.

A 2016 JAMA Internal Medicine analysis found that 25.3% of men who received a new testosterone prescription between 2009 and 2013 had no prior testosterone measurement documented, raising concerns about prescribing practices that fall outside guideline-supported indications [16].

Cardiovascular Risk: What Current Evidence Says

Cardiovascular risk remains the most actively debated aspect of testosterone prescribing across all jurisdictions.

TRAVERSE Trial Data

The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and pre-existing or high-risk cardiovascular disease) published in NEJM in 2023 found that testosterone replacement was non-inferior to placebo for MACE (HR 0.96, 95% CI 0.78 to 1.17), but was associated with a higher rate of atrial fibrillation (3.5% vs. 2.4%, P=0.001) and pulmonary embolism (0.9% vs. 0.5%, P=0.04) [17]. Regulators in the US and EU are actively reviewing whether label updates are warranted in light of these findings.

FDA Response to TRAVERSE

Following TRAVERSE, the FDA has communicated that existing cardiovascular warnings on testosterone labels remain appropriate while further review is ongoing [8]. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reached a similar holding position as of late 2023 [9].

Anti-Doping Status Across All Four Jurisdictions

WADA classifies all exogenous androgens, including testosterone enanthate, as prohibited at all times under section S1 of the 2024 Prohibited List [10]. This prohibition applies regardless of whether the athlete holds a valid medical prescription.

Athletes with documented hypogonadism may apply for a Therapeutic Use Exemption (TUE). TUE criteria require documented primary or secondary hypogonadism confirmed by two morning testosterone measurements below 200 ng/dL (6.9 nmol/L), a more stringent threshold than clinical prescribing guidelines in all four jurisdictions [10].

A 2019 analysis in the British Journal of Sports Medicine found that TUE applications for testosterone represented 7.8% of all TUE requests across 35 international federations, making it one of the most commonly exempted drug classes [18].

Practical Prescribing Considerations Across Borders

Patients traveling between jurisdictions should carry a physician letter, the original pharmacy label, and, where required, a copy of the controlled-substance prescription. The US DEA does not recognize foreign prescriptions; a traveler entering the US with testosterone enanthate without a US practitioner's prescription may face federal customs charges even if the drug was legally dispensed abroad [7].

Telehealth prescribing of Schedule III substances in the US requires compliance with the DEA's 2023 telehealth prescribing rules, which reinstated in-person visit requirements for controlled substances following the expiration of COVID-era flexibilities, though proposed rules as of mid-2025 are still under notice-and-comment [6].

In the UK, online prescribing of testosterone is legal only through MHRA-registered online pharmacies with a GMC-registered prescriber who has conducted an adequate clinical assessment, including documented laboratory results [13].